CRVO Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases...

Stats
Today's Volume	30 978.00
Average Volume	30 773.00
Market Cap	146.98M
EPS	$0 ( 2024-04-01 )
Next earnings date	( $-0.390 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.26
ATR14	$0.234 (0.98%)

Insider Trading

Date	Person	Action	Amount	type
2024-02-26	Boger Joshua S	Buy	495 995	Common Stock
2024-02-26	Boger Joshua S	Sell	36	Common Stock
2024-02-26	Boger Joshua S	Sell	495 995	Pre-Funded Common Stock Purchase Warrant
2024-02-12	Boger Joshua S	Buy	10 000	Stock Option (Right to Buy)
2024-02-07	Boger Joshua S	Buy	0	Common Stock

INSIDER POWER
15.11
Last 11 transactions
Buy: 680 716 \| Sell: 496 031

Volume Correlation

Long: -0.12 (neutral)

Short: -0.82 (strong negative)

Signal:(36.361) Neutral

CervoMed Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

CervoMed Inc. Correlation - Currency/Commodity

-0.26
( neutral )

-0.32
( neutral )

0.00
( neutral )

-0.15
( neutral )

0.30
( neutral )

0.49
( neutral )

Financial Reports:

No articles found.

CervoMed Inc.

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, and brain stroke recovery. The company is based in Boston, Massachusetts.